Because blocking of OCT4 or MYCN reduces MYCN expression, simultaneous blocking of OCT4 or MYCN with this CRC, with a focus on targeting transcription factors including HAND2, PHOX2B, and GATA3, may be an effective therapeutic approach for NB. This evidence concerns the gene GATA3 and neuroblastoma.